RecruitingPhase 3NCT07187570

RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care

RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Open-label Treatment With Dapagliflozin or Usual Care

Sponsor

Region Stockholm

Enrollment

1,600 participants

Start Date

Jun 3, 2025

Study Type

INTERVENTIONAL

Conditions

Atrial Fibrillation (AF)

Summary

The goal of this clinical trial is to learn if drug dapagliflozin, a sodium-glucose transport-2 inhibitor, works to treat atrial fibrillation in adults. The main question it aims to answer is: • Does the drug dapagliflozin reduce the recurrence rate of atrial fibrillation? Researchers will compare drug dapagliflozin to standard therapy to see if drug dapagliflozin reduce the recurrence of atrial fibrillation. Persons with atrial fibrillation who are planned for an electric cardioversion will: * Take the drug dapagliflozin, or no drug, once a day for a maximum of 56 days * Undergo a planned electric cardioversion of the atrial fibrillation * Record the rhythm with a hand-held device that transmits the signal to researchers during the study period, but no longer than for 56 days

Eligibility

Min Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing whether dapagliflozin (a diabetes/heart drug) can help prevent atrial fibrillation (AFib) from coming back after a patient undergoes electrical cardioversion to restore normal heart rhythm. **You may be eligible if...** - You have AFib confirmed on an ECG and are scheduled for electrical cardioversion within 7–26 days - You are 55 years of age or older - You are willing to give written informed consent **You may NOT be eligible if...** - You are already taking an SGLT2 inhibitor medication - You have been diagnosed with heart failure - You have type 1 diabetes - Your kidney function is significantly reduced (eGFR below 25) - You have had a pulmonary vein isolation procedure within the past 3 months or plan to have one during the study - You have a medical reason that prevents you from taking SGLT2 inhibitors Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.